III. Role of allotransplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia

Annals of Oncology

Volumn 22, Issue , 2011, Pages iv36-iv39

  Dreger, P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864127817     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr169     Document Type: Conference Paper

References (21)

1. Sant, M., Allemani, C., Tereanu, C., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116 (2010), 3724–3734.
2. Dreger, P., Allotransplantation for chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2009;, 2009, 596–603.
3. Dreger, P., Döhner, H., Ritgen, M., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 116 (2010), 2438–2447.
4. Stilgenbauer, S., Zenz, T., Winkler, D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H trial of the GCLLSG. J Clin Oncol 27 (2009), 3994–4001.
5. Dreger, P., Corradini, P., Kimby, E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21 (2007), 12–17.
6. Gratwohl, A., Stern, M., Brand, R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115 (2009), 4715–4726.
7. Witzens-Harig, M., Dreger, P., Autologous transplantation of follicular lymphoma in the era of rituximab. Leuk Lymphoma 51 (2010), 967–974.
8. Thomson, K.J., Morris, E.C., Bloor, A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27 (2009), 426–432.
9. van Besien, K., Carreras, J., Bierman, P.J., et al. Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 15 (2009), 554–563.
10. Delgado, J., Canals, C., Attal, M., et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia, 2010 epub Dec 24.
11. Hari, P., Carreras, J., Zhang, M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 14 (2008), 236–245.
12. Oliansky, D.M., Gordon, L.I., King, J., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 16 (2010), 443–468.
13. Tam, C.S., Bassett, R., Ledesma, C., et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113 (2009), 4144–4152.
14. Dietrich, S., Tielesch, B., Rieger, M., et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer, 2010 epub Nov 29.
15. Sirvent, A., Dhedin, N., Michallet, M., et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 16 (2010), 78–85.
16. Rezvani, A.R., Norasetthada, L., Gooley, T., et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 143 (2008), 395–403.
17. van Kampen, R.J., Canals, C., Schouten, H.C., et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 29 (2011), 1342–1348.
18. Le Gouill, S., Milpied, N., Buzyn, A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26 (2008), 2264–2271.
19. Kyriakou, C., Canals, C., Finke, J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 27 (2009), 3951–3958.
20. Corradini, P., Dodero, A., Zallio, F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004), 2172–2176.
21. Duarte, R.F., Canals, C., Onida, F., et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28 (2010), 4492–4499.